EANS-Adhoc: Marseille-Kliniken AG: Uwe Bergheim and Prof. Matthias Schönermark
announce their resignation from the supervisory board
--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Resignation of members of the supervisory board
19.10.2012
Hamburg, 19 October 2012 - Following an extraordinary general meeting today,
Messrs Uwe Bergheim and Prof. Dr. med. Matthias P. Schönermark have announced
their intention to resign from the supervisory board of Marseille-Kliniken AG
(ISIN DE0007783003, WKN 778300, MKA) with the end of the annual general meeting
which is planned for 3 December 2012.
end of ad-hoc-announcement
================================================================================
About Marseille-Kliniken AG:
Marseille-Kliniken AG (ISIN DE0007783003, WKN 778300, MKA) with its 57
residential care facilities, three residential units for assisted living and
about 4,700 employees is a market leading listed company on health care in
Germany. The business model is significantly influenced by the demographic
development. Therefore Marseille-Kliniken AG has a secured future. Short-term
economic fluctuations on the other hand exert only a minor influence. As a
consistently modern company with strong focus on quality, the private enterprise
is in a good position within a competitive environment primarily characterized
by regionally active charities.
Further inquiry note:
Hillermann Consulting
Jan Pahl
Investor Relations for Marseille-Kliniken AG
Poststraße 14-16
20354 Hamburg
Germany
Tel.: +49 - (0)40 / 3202791-0
www.marseille-kliniken.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
issuer: Marseille-Kliniken AG
Alte Jakobstraße 79/80
D-10179 Berlin
phone: +49 (0)30 246 32-400
FAX: +49 (0)30 246 32-401
mail: info@marseille-kliniken.de
WWW: http://www.marseille-kliniken.de
sector: Pharmaceuticals
ISIN: DE0007783003
indexes: CDAX, Classic All Share, Prime All Share
stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing:
Hamburg, regulated dealing/prime standard: Frankfurt
language: English